SEMA / IGF-1 LR3Check methods and identity
What separate Alzheimer’s studies measured for these two molecules
3 numbered sourcesSource years 2024, 2026
Peptides are short amino-acid chains connected by peptide bonds. Some activate receptors and change how cells handle signals. Semaglutide is a modified GLP-1 receptor agonist peptide. IGF-1 LR3 is an engineered growth-factor protein. Researchers have studied each in connection with Alzheimer’s disease in very different settings. The human semaglutide trials and an older IGF-1 LR3 mouse experiment show how the choice of outcome shapes the conclusion. [1, 2]
The evoke and evoke+ trials randomly assigned people with early symptomatic Alzheimer’s disease to oral semaglutide or placebo. The main comparison assessed change in a clinical scale that combines observations about cognition and daily function. At 104 weeks, neither trial found a significant difference in progression on that measure. These trials were designed to test the clinical outcome in people who already had early symptoms. [1]
In a separate study, investigators tested IGF-1 LR3 in male mice engineered to develop some features of Alzheimer’s disease. The researchers examined the animals’ behavior and brain tissue. They reported changes in certain amyloid plaque measurements, but they did not observe a significant preservation of cognitive function in their tests. Changes in tissue pathology and changes in performance were separate outcomes, even within this one experiment. [2]
Reading these findings together can help identify what was measured at each level. The mouse tissue findings concern a growth-factor analog in a particular model. The clinical scale findings concern a particular semaglutide formulation and population. Neither study included both molecules. There is no comparative clinical result for the catalog pair in these sources, and the investigated uses do not establish an Alzheimer’s indication. [1, 2, 3]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.Jeffrey L. Cummings et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet (publication 2026-03-19). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
- 2.M. G. Engel et al. Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. Journal of Alzheimer’s Disease (publication 2024-11-29). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
